Roche/Evotec's Alzheimer's candidate fails
This article was originally published in Scrip
Roche and Evotec look set to drop their MAO-B inhibitor sembragiline from development for Alzheimer's following disappointing Phase IIb data. The product appears to be a late swansong for this mechanism of action in Alzheimer's: previous similar candidates failed around 15 years ago, and the only other investigational MAO-B inhibitors still in the running are at the preclinical stage.
You may also be interested in...
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent
Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.
Topline Phase II data for the antibody-drug conjugate tisotumab vedotin put it on a swift path towards approval in cervical cancer.